Zhejiang Wecome Pharmaceutical Company Limited (SHE:300878)
China · Delayed Price · Currency is CNY 28.68
-0.26 (-0.90%)
Oct 14, 2026, 1:35 PM CST
SHE:300878 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,074 | 3,624 | 2,141 | 3,673 | 3,591 | 4,246 | |
Market Cap Growth | 28.61% | 69.28% | -41.72% | 2.30% | -15.42% | 4.95% |
Enterprise Value | 4,127 | 3,642 | 2,172 | 3,685 | 3,506 | 3,996 |
Last Close Price | 28.94 | 25.51 | 14.94 | 24.77 | 24.21 | 28.27 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | - | 73.57 | 44.00 |
PS Ratio | 17.36 | 16.09 | 6.10 | 7.07 | 6.74 | 6.71 |
PB Ratio | 4.56 | 3.92 | 1.82 | 2.61 | 2.55 | 3.01 |
P/TBV Ratio | 4.79 | 4.12 | 1.92 | 2.77 | 2.69 | 3.17 |
P/OCF Ratio | - | 54.01 | - | 63.02 | 24.73 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 17.58 | 16.17 | 6.19 | 7.09 | 6.58 | 6.31 |
EV/EBITDA Ratio | - | - | - | 137.76 | 41.71 | 40.93 |
EV/EBIT Ratio | - | - | - | - | 64.63 | 47.80 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.26 | 0.18 | 0.25 | 0.31 | 0.23 | 0.06 |
Debt / EBITDA Ratio | - | - | - | 16.27 | 3.30 | 0.74 |
Net Debt / Equity Ratio | 0.04 | 0.02 | 0.03 | -0.10 | 0.11 | -0.14 |
Net Debt / EBITDA Ratio | -1.21 | -0.27 | -0.41 | -5.25 | 1.86 | -2.03 |
Net Debt / FCF Ratio | -0.70 | -214.11 | -0.25 | 1.73 | -5.54 | 0.83 |
Asset Turnover | 0.17 | 0.16 | 0.19 | 0.26 | 0.30 | 0.38 |
Inventory Turnover | 2.07 | 2.07 | 1.64 | 1.91 | 1.78 | 1.93 |
Quick Ratio | 1.13 | 1.61 | 1.96 | 1.95 | 2.09 | 2.98 |
Current Ratio | 1.38 | 2.07 | 2.57 | 2.36 | 2.50 | 3.74 |
Return on Equity (ROE) | -18.85% | -21.91% | -11.22% | -0.50% | 3.51% | 6.91% |
Return on Assets (ROA) | -3.89% | -5.39% | -5.44% | -0.63% | 1.88% | 3.15% |
Return on Invested Capital (ROIC) | -9.14% | -11.62% | -13.03% | -1.40% | 3.06% | 8.01% |
Return on Capital Employed (ROCE) | -9.20% | -11.70% | -11.40% | -1.20% | 3.60% | 5.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -4.51% | -6.27% | -6.89% | -0.24% | 1.36% | 2.27% |
FCF Yield | -1.37% | -0.00% | -7.20% | -2.21% | -0.79% | -5.63% |
Dividend Yield | - | - | 0.94% | 1.01% | - | 1.06% |
Payout Ratio | - | - | - | - | 93.71% | 83.93% |
Buyback Yield / Dilution | -0.51% | -1.17% | 4.09% | -3.96% | 0.32% | -19.60% |
Total Shareholder Return | -0.51% | -1.17% | 5.03% | -2.95% | 0.32% | -18.53% |